Viatris, Inc. (VTRS)
19.95
+0.07
(+0.35%)
USD |
NASDAQ |
Nov 20, 10:10
Viatris Cash from Operations (Quarterly) : 899.40M for Sept. 30, 2026
Cash from Operations (Quarterly) Chart
Historical Cash from Operations (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2026 | 899.40M |
| June 30, 2026 | 381.80M |
| March 31, 2026 | 388.30M |
| December 31, 2025 | 815.80M |
| September 30, 2025 | 744.90M |
| June 30, 2025 | 219.70M |
| March 31, 2025 | 535.50M |
| December 31, 2024 | 482.70M |
| September 30, 2024 | 826.50M |
| June 30, 2024 | 379.10M |
| March 31, 2024 | 614.60M |
| December 31, 2023 | 479.40M |
| September 30, 2023 | 834.10M |
| June 30, 2023 | 514.90M |
| March 31, 2023 | 971.20M |
| December 31, 2022 | 142.60M |
| September 30, 2022 | 869.00M |
| June 30, 2022 | 802.50M |
| March 31, 2022 | 1.138B |
| December 31, 2021 | 523.10M |
| September 30, 2021 | 1.086B |
| June 30, 2021 | 559.40M |
| March 31, 2021 | 848.80M |
| December 31, 2020 | 36.20M |
| September 30, 2020 | 525.00M |
| Date | Value |
|---|---|
| June 30, 2020 | 379.50M |
| March 31, 2020 | 291.10M |
| December 31, 2019 | 686.70M |
| September 30, 2019 | 487.80M |
| June 30, 2019 | 668.90M |
| March 31, 2019 | -39.70M |
| December 31, 2018 | 636.10M |
| September 30, 2018 | 653.60M |
| June 30, 2018 | 430.20M |
| March 31, 2018 | 621.80M |
| December 31, 2017 | 495.50M |
| September 30, 2017 | 548.60M |
| June 30, 2017 | 571.50M |
| March 31, 2017 | 449.20M |
| December 31, 2016 | 349.50M |
| September 30, 2016 | 1.201B |
| June 30, 2016 | 416.60M |
| March 31, 2016 | 80.50M |
| December 31, 2015 | 652.00M |
| September 30, 2015 | 974.80M |
| June 30, 2015 | 114.70M |
| March 31, 2015 | 267.00M |
| December 31, 2014 | 126.60M |
| September 30, 2014 | 440.70M |
| June 30, 2014 | 179.40M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Quarterly) Benchmarks
| Pacira Biosciences, Inc. | 50.07M |
| Pfizer Inc. | 5.375B |
| Eli Lilly & Co. | 11.40B |
| Merck & Co., Inc. | 6.558B |
| Amphastar Pharmaceuticals, Inc. | 43.30M |
Cash from Operations (Quarterly) Related Metrics
| Cash from Investing (Quarterly) | 292.30M |
| Cash from Financing (Quarterly) | -289.80M |
| Free Cash Flow | 1.971B |
| Free Cash Flow Per Share (Quarterly) | 0.7059 |
| Free Cash Flow to Equity (Quarterly) | 855.20M |
| Free Cash Flow to Firm (Quarterly) | 524.41M |
| Free Cash Flow Yield | 8.62% |